Cytomegalovirus Viremia in Renal Transplant Recipients After Influenza Vaccination

Akshay M. Khatri 1, Ilan Berlinrut 1, Robin Koshy 1, Madhu Bhaskaran 2

1. Infectious Diseases, Northwell Health, Manhasset, USA 2. Nephrology and Transplant Nephrology, Northwell Health, Manhasset, USA

Corresponding author: Akshay M. Khatri, akshay1210@gmail.com

Abstract

Vaccination with the inactivated influenza vaccine is routinely recommended for all patients before and after transplant, with reduction in complications noted in transplant recipients. The vaccine is relatively well tolerated with few mild side effects. Cytomegalovirus (CMV) infection can reactivate in both solid organ transplant and hematopoietic stem cell transplant recipients, with some patients progressing to disease. There are multiple factors known to contribute to reactivation and subsequent CMV disease, however vaccination has not been reported as a specific risk factor.

We report on two renal transplant recipients who were seen to develop CMV viremia and CMV disease after receiving the Influenza vaccine. We review the literature regarding viremia occurring after vaccination in HIV patients (a similar group of immunocompromised patients).

Categories: Allergy/Immunology, Infectious Disease, Transplantation
Keywords: cytomegalovirus (cmv), influenza vaccine, renal transplant, viremia

Introduction

The inactivated Influenza vaccine is recommended in all solid organ transplant recipients (SOTRs) and it can be administered either before or one month after transplantation [1]. In SOTRs, it was associated with a decrease in severity of influenza disease (as determined by occurrence of pneumonia and incidence of intensive care unit admission). The vaccine is relatively well tolerated - there have been reports of mild reactions, with some vaccine strains being associated with risk of rejection [1].

Cytomegalovirus (CMV) can reactivate in both solid organ transplant and hematopoietic stem cell transplant recipients [2, 3]. There are multiple patient- and therapy-related factors known to contribute to reactivation and subsequent CMV disease [2-6].

Vaccination has reported to cause viremia with human immunodeficiency virus (HIV) in patients who are HIV-infected, even those who are on potent anti-retroviral therapy (ART) [7, 8]. Despite the extensive research, vaccination has not been reported to be a risk factor for CMV viremia in transplant recipients.

In this case report, we describe two cases of kidney transplant recipients who received the influenza vaccine and developed cytomegalovirus (CMV) viremia thereafter. Due to the paucity of literature regarding viremia after vaccination in transplant recipients, we review the studies

How to cite this article
Khatri A M, Berlinrut I, Koshy R, et al. (August 12, 2020) Cytomegalovirus Viremia in Renal Transplant Recipients After Influenza Vaccination. Cureus 12(8): e9680. DOI 10.7759/cureus.9680
reporting viremia occurring after vaccination in HIV patients (a similar group of immunocompromised patients).

**Case Presentation**

**Patient 1**

A 50-year-old female with past medical history of hypertension, autosomal dominant polycystic kidney disease and end-stage renal disease (on hemodialysis) underwent a renal transplant from a living unrelated donor in June 2016.

She received the influenza vaccine in November 2017 at the outpatient transplant nephrology clinic. She presented to her next appointment eight days later with complaints of fevers with chills, night sweats, lethargy, headaches, myalgias, nausea, anorexia, left-sided pleuritic chest pain and multiple episodes of watery, non-bloody diarrhea. She was directed to the emergency department for further evaluation.

She denied sick contacts, recent travel, medication changes or medication non-compliance. At the time of admission, she was on prednisone 5 mg PO (oral) QD, mycophenolate mofetil (MMF) 560 mg PO QID, tacrolimus 0.5 mg PO BID.

Her vitals on admission were significant for temperature 101.7 F, heart rate 100/minute, blood pressure 118/79 mm Hg, respirations 18/minute and oxygen saturation 98% on room air. Physical exam revealed no acute abnormalities.

Admission labs were significant for white blood cell (WBC) 2,070/mm$^3$ [normal range (N): 3,800-10,500/mm$^3$], absolute neutrophil count (ANC) 1,865/mm$^3$ [N: 1,800-7,400/mm$^3$], lymphocyte count 500/mm$^3$ [N: 1,000-3,300/mm$^3$], platelets 108,000/mm$^3$ [N: 150,000-400,000/mm$^3$], aspartate transaminase (AST) 81 U/l [N: 10-40 U/l], alanine transaminase (ALT) 87 U/l [N: 10-45 U/l], alkaline phosphatase (ALP) 137 U/l [N: 40-120 U/l] and normal renal function. Electrocardiogram revealed sinus rhythm with no acute changes. Chest radiography and computed tomography (CT) ruled out the presence of pneumonia. Abdominal ultrasound showed polycystic liver and kidneys, contracted gallbladder with negative sonographic Murphy’s sign. CT of the abdomen and pelvis confirmed polycystic liver and kidneys, as well as mural thickening of ascending colon with mild surrounding inflammatory changes (suggestive of colitis) (Figures 1, 2).
FIGURE 1: Computed tomography (CT) scan of abdomen and pelvis showing presence of cysts in liver (blue arrows) and cysts in the kidney (yellow arrows)
Urinalysis was not suggestive of infection. Respiratory viral panel multiplex test was negative. Clostridium difficile toxin test was negative. Stool cultures were negative. Stool microscopy was negative for ova and parasites. Urine cultures revealed Escherichia coli (10,000–49,000 CFU/ml) combined with normal urogenital flora. Blood cultures revealed no growth. Testing for acute hepatitis A, B and C viruses was negative. Epstein-Barr virus serology revealed prior infection. BK virus DNA, Parvovirus B19 DNA and adenovirus DNA were not detected by specific polymerase chain reaction (PCR) tests.

Infectious diseases service was consulted. Given the presence of leukopenia, thrombocytopenia, transaminitis and multi-systemic symptoms, there was concern for an ongoing viral process. She was started on valganciclovir 900 mg PO BID for presumed CMV disease, with intravenous fluid support. The E. coli in the urine was thought to be a colonization and she was successfully monitored off antibiotics.

She continued to have persistent fevers and diarrhea, with worsening leukopenia (lowest WBC count 1700/mm³ with lowest ANC 800/mm³), thrombocytopenia (nadir 86,000/mm³) and liver function abnormalities (AST 139 U/l, ALT 135 U/l, ALP 167 U/l). Given the persistent symptoms and worsening laboratory parameters, MMF was discontinued. Serum CMV PCR testing revealed 154,697 IU/ml (5.19 log10 IU/ml) [lower limit of assay detection 60 IU/ml (1.78 log10 IU/ml)]. Gastroenterology service was consulted for worsening liver function abnormalities and they attributed the clinical picture to systemic CMV infection.

She had clinical improvement, with improving CMV PCR tests [504 IU/ml (2.70 log10 IU/ml)] after 12 days of antiviral therapy. She was discharged on the twelfth day of hospital stay, with recovery of WBC count to 5,600/mm³ and platelets 147,000/mm³.

She was followed up by in the outpatient transplant nephrology and infectious diseases clinics. CMV PCR was negative 60 days after initiation of antiviral therapy and she was restarted on a lower dose of MMF. After the second negative CMV PCR a week later, MMF dose was increased and valganciclovir was decreased to prophylactic dosing. She received valganciclovir for a total of 87 days.

**Patient 2**

A 62-year-old female with past medical history of endometriosis, hypertension, chronic kidney disease (likely from anti-inflammatory drug use for management of endometriosis) was being followed in the transplant nephrology clinic. She received a deceased donor kidney transplant in 1998 that failed in March 2018 and was subsequently on hemodialysis. She received a second renal transplant from a deceased unrelated donor in June 2019.

She received the Influenza vaccine at the end of September 2019. On routine outpatient labs performed a week later, she was noted to have detectable CMV viral levels [4,983 IU/ml (5.70 log10 IU/ml)] without any symptoms. The levels continued to rise over the course of two months [214,823 IU/ml (5.33 log10 IU/ml)], with no improvement after switching from valganciclovir 450 mg QD to valganciclovir 900 mg QD. She was noted to have worsening...
leukopenia (WBC 1,260/mm$^3$), so she was admitted for further management.

On admission, she reported multiple episodes of non-bloody, foul-smelling diarrhea. She denied sick contacts, recent travel, medication changes or medication non-compliance. Her home medications consisted of tacrolimus ER 8 mg QD, prednisone 5 mg QD, MMF 1000 mg BID, sulfamethoxazole-trimethoprim single-strength tablet QOD, valganciclovir 450 mg QD.

She was hemodynamically stable on examination. Physical examination revealed no abnormalities. Admission labs revealed WBC count 1,480/mm$^3$ (ANC 950/mm$^3$ and lymphocyte count 270/mm$^3$), hemoglobin 11.1 g/dl (N: 13-17 g/dL), blood urea nitrogen (BUN) 20 mg/dL [N: 7-25 mg/dL], creatinine 1.55 mg/dl [N: 0.50-1.50 mg/dL], ALP 124 U/l. Chest radiograph revealed clear lungs. BK virus and Parvovirus B19 DNA PCR tests were negative.

MMF and valganciclovir was held on admission. Infectious diseases service was consulted and she was started on renally-dosed intravenous (IV) ganciclovir (2.5 mg/kg QD) and letermovir 480 mg QD PO. Given the lack of response to outpatient valganciclovir therapy, a sample was sent for CMV resistance testing. With improvement in her creatinine clearance, the ganciclovir dosing was subsequently adjusted. WBC nadir during the hospital stay was 1,450/mm$^3$ (ANC 780/mm$^3$), with subsequent recovery due to intravenous antivirals and one dose of filgrastim.

CMV resistance tests revealed the presence of two different populations of virus - wild type and a strain exhibiting resistance at M460V and C603W (two out of seven mutations conferring resistance to ganciclovir). No resistance was noted to cidofovir or foscarnet. She was discharged on IV ganciclovir and oral letermovir. The final duration of therapy would be determined by outpatient follow-up with infectious diseases and transplant nephrology. She was to continue tacrolimus ER 3 mg QD PO and prednisone 5 mg QD PO at home.

**Discussion**

There are multiple risk factors linked to CMV viremia and disease in SOTRs and after hematopoietic stem cell transplant. These include older age, female sex, blood group A, decreased creatinine clearance, allograft impairment, CMV serostatus prior to transplant (donor seropositive-recipient seronegative OR recipient seropositive), transplantation type, use of T-cell depleted stem cell grafts, use of anti-thymocyte globulin before transplant, and occurrence of graft-versus-host disease (GvHD) [2-6]. Vaccination has not been previously reported as a risk factor for CMV viremia.

The influenza virus vaccine administered seasonally is a trivalent or quadrivalent inactivated vaccine [1]. It is a T cell-dependent common recall antigen and has been shown to induce T cell activation and type 1 cytokine production (such as interleukin-2 and interferon-γ) [7]. There is a paucity of data on the effects of influenza vaccination leading to viremia in solid organ transplant recipients. Thus, we reviewed the data available in human immunodeficiency virus (HIV)-infected patients, another subset of immunocompromised patients.

The research on the effect of influenza virus on HIV replication has produced conflicting results. Some studies have shown that influenza vaccination results in increased HIV replication (and subsequently increased viremia) in patients with uncontrolled or partially controlled viral replication [7-10]. Other studies have shown that vaccination did not result in increased HIV replication [11-16]. It is believed that a transient increase in plasma HIV RNA levels occurs during the first and second weeks after vaccination - this may have been missed in some studies due to less frequent sampling [15]. A randomized controlled trial comparing the effect of vaccines (versus placebo) on HIV transcription and immune activation reported an
increased HIV transcription, without increase in HIV DNA or plasma HIV RNA [17]. Vaccination is seen to produce a systemic inflammatory response - this may cause upregulation of viral production from chronically infected cells or activation of latently infected bystander cells [8,18]. This ultimately leads to an increase in RNA levels in patients who have ongoing low-level viral replication [8].

In some transplant recipients, influenza-like illness has been reported after vaccination [19]. SOTRs are maintained in a state of prolonged immunosuppression after transplant. Thus, there is a possibility that influenza vaccination may lead to transient increase in CMV viral load and subsequent viremia (similar to the transient viremia seen in HIV patients). The exact mechanisms leading to viremia are not known – however the potential role of estrogen in transduction of CMV genes [2], as well as the effects of systemic inflammatory response (induced by vaccination) on viral replication [8,18] indicate that molecular and genetic mechanisms may play a role.

Both patients had a temporal association of onset of CMV viremia with administration of the influenza vaccine (Table 1). They were older females at high risk of CMV reactivation (donor CMV seropositive/recipient CMV seronegative). Patient 2 was on CMV prophylaxis, while patient 2 was not receiving valganciclovir (per our institutional protocol of CMV prophylaxis until six months post-transplant). They reported compliance with their home medications, with no recent increases in their maintenance immunosuppression. Patient 1 had an episode of antibody-mediated rejection, while patient 2 had an upper respiratory bacterial infection in the preceding months – these resolved completely with appropriate therapy. They had no concurrent inflammatory disease processes at the time of vaccination. Lab testing demonstrated high CMV DNA levels with concomitant leukopenia, neutropenia and lymphopenia. There were no additional factors identified to have contributed to CMV viremia. The CMV viremia was severe enough to warrant therapeutic antiviral therapy and changes in their immunosuppression regimen. We thus believe that CMV viremia resulted from the prior vaccination in our patients.

| Sr. No. | Characteristic | Patient 1                                      | Patient 2                                      |
|---------|---------------|------------------------------------------------|------------------------------------------------|
| 1       | Type of donor  | Living unrelated donor                          | Deceased donor                                 |
| 2       | Initial transplant / Re-transplant | Initial transplant                                      | Re-transplant                                 |
| 3       | Donor CMV status | CMV seropositive                              | CMV seropositive                               |
| 4       | Recipient CMV status | CMV seronegative                             | CMV seronegative                               |
| 5       | Induction immunosuppressive regimen | 1. Anti-thymocyte globulin 2. Methylprednisolone  3. IVIG | 1. Anti-thymocyte globulin 2. Methylprednisolone |
| 6       | Recent inflammatory disease processes (allograft rejection, infection) | Donor-specific antibody mediated rejection | Upper respiratory infection                     |
| 7       | Time period between transplant and inflammatory disease process | 4 months | 1 month                                      |
| 8       | Treatments for inflammatory disease | 1. IVIG 2. Rituximab 3. Apheresis               | Amoxicillin                                    |
|   |   |   |   |
|---|---|---|---|
| 9 | Duration of inflammatory disease process | 1 month | 1 week |
| 10 | Prior episodes of CMV reactivation | None | None |
| 11 | Primary / Secondary CMV prophylaxis | Off CMV prophylaxis at the time of disease presentation | Primary prophylaxis |
| 12 | Recent increase in maintenance immunosuppressive regimen | None | None |
| 13 | Age at time of presentation | 55 years | 62 years |
| 14 | Time period between transplant and presentation | 17 months | 3 months |
| 15 | Time period between vaccination and presentation | 8 days | 7 days |
| 16 | Prophylactic medications at the time of presentation | SMX-TMP SS 1 tablet PO QD | Valganciclovir 450 mg QD |
| 17 | Immunosuppressive regimen at the time of presentation | Prednisone 5 mg PO QD MMF 360 mg PO QID Tacrolimus 0.5 mg PO BID | Prednisone 5 mg QD MMF 1000 mg BID Tacrolimus ER 8 mg QD |
| 18 | Initial symptoms | Fevers, chills, night sweats lethargy, headaches, myalgias, nausea, anorexia, pleuritic chest pain watery, non-bloody diarrhea | Watery, non-bloody diarrhea |
| 19 | Initial laboratory abnormalities | WBC 2.070/mm$^3$ ANC 1.865/mm$^3$ Platelets 108,000/mm$^3$ AST 81 IU/l ALT 87 IU/l ALP 137 IU/l | WBC 1,480/mm$^3$ ANC 950/mm$^3$ Hemoglobin 11.1 g/dl BUN 20 mg/dl Creatinine 1.53 mg/dl ALP 124 IU/l |
| 20 | Initial lymphocyte count [N: 1,000-3,300/mm$^3$] | 500/mm$^3$ | 270/mm$^3$ |
| 21 | CMV viral load [lower limit of assay detection: 60 IU/ml (1.78 log10 IU/ml)] | 154,697 IU/ml (5.19 log10 IU/ml) | 214,823 IU/ml (5.33 log10 IU/ml) |
| 22 | Treatment regimen | Valganciclovir 900 mg PO BID | 1. Ganciclovir 2.5 mg/kg IV QD (initial dosing) 2. Letemovir 480 mg PO QD |
| 23 | Changes in immunosuppressive regimen | Temporary discontinuation of MMF | 1. Temporary discontinuation of MMF 2. Decrease in Tacrolimus dosing (Tacrolimus ER 3 mg QD PO) |
| 24 | Patient outcome | Control of CMV viremia and recovery of cell counts | Control of CMV viremia and recovery of cell counts |
| 25 | Graft outcome | Stable allograft function | Stable allograft function |
TABLE 1: Patient characteristics

ALT: Alanine transaminase; ANC: Absolute neutrophil count; ALP: Alkaline phosphatase; AST: Aspartate transaminase; BID: Every 12 hours; BUN: Blood urea nitrogen; CMV: Cytomegalovirus; ER: Extended release; IV: Intravenous; IVIG: Intravenous immune-globulin; PO: Oral; QD: Every twenty-four hours; QID: Every six hours; QOD: Every forty-eight hours; SMX-TMP: Sulfamethoxazole-trimethoprim; SS: Single-strength; WBC: White blood cell count.

One meta-analysis concluded that the influenza vaccine was associated with statistically significant protection against influenza-like illness in immunocompromised patients, including SOTRs [20]. Given the significant proven benefits of vaccination in SOTRs (versus the risk of potential viremia), we firmly believe that all SOTRs should get the inactivated influenza vaccine and other vaccines as per the latest guidelines [1]. Through this case report, we wish to highlight the finding of CMV viremia occurring after influenza vaccination, with no other identified triggers. Further research and accumulation of cases is needed to investigate the strength of this association, to determine the mechanisms that resulted in CMV viremia and to recognize the risk factors leading to progression from viremia to clinically relevant CMV disease.

Conclusions

Vaccination may lead to transient viral replication in immunocompromised patients, such as HIV-infected patients (likely due to genetic and immune-mediated mechanisms). Similarly, we believe that influenza vaccination led to transient CMV viremia and CMV disease in our renal transplant recipients on potent immunosuppressive therapies. Further research is needed to assess the strength of this correlation, the mechanisms causing viremia and the risk of progression to clinical disease. Until then, clinicians must continue vaccination of SOTRs per the guidelines, but must also remember to enquire about recent vaccination when evaluating SOTRs with new onset CMV viremia.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. Not applicable issued approval Not applicable. The research met our institutional definition of a case report (a medical chart review of 3 or fewer patients). Thus institutional research board review was not needed and the need for consent was waived. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Danziger-Isakov L, Kumar D; AST ID Community of Practice: Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019, 33:13563. 10.1111/ctr.13563
2. Freeman RB, Paya C, Pescevitz MD, et al.: Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients.
3. Khoury JA, Storch GA, Bohl DL, et al.: Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant. 2006, 6:2134-2143. 10.1111/j.1600-6143.2006.01413.x

4. Abbott KC, Hypolite IO, Viola R, et al.: Hospitalizations for cytomegalovirus disease after renal transplantation in the United States. Ann Epidemiol. 2002, 12:402-409. 10.1016/s1047-2797(01)00283-6

5. Wu JL, Ma HY, Lu CY, et al.: Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients. J Microbiol Immunol Infect. 2017, 50:307-315. 10.1016/j.jmii.2015.07.011

6. Einollahi B: Cytomegalovirus infection following kidney transplantation: a multicenter study of 3065 cases. Int J Organ Transplant Med. 2012, 3:74-78.

7. Vigano A, Bricalli D, Trabattoni D, et al.: Immunization with both T cell-dependent and T cell-independent vaccines augments HIV viral load secondarily to stimulation of tumor necrosis factor alpha. AIDS Res Human Retroviruses. 1998, 14:727-734. 10.1089/aid.1998.14.727

8. Günthard HF, Wong JK, Spina CA, et al.: Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis. 2000, 181:522-531. 10.1086/315260

9. Ramilo O, Hicks PJ, Borvak J, et al.: T cell activation and human immunodeficiency virus replication after influenza immunization of infected children. Pediatr Infect Dis J. 1996, 15:197-205. 10.1097/00002248-199603000-00004

10. Kosalaraksa P, Srirompotong U, Newman RW, Lumbiganon P, Wood JM: Serological response to trivalent inactive influenza vaccine in HIV-infected children with different immunologic status. Vaccine. 2011, 29:3055-3060. 10.1016/j.vaccine.2011.01.091

11. Glesby MJ, Hoover DR, Farzadegan H, Margolick J, Saah AJ: The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. J Infect Dis. 1996, 174:1332-1356. 10.1093/infdis/174.6.1332

12. Wu JL, Ma HY, Lu CY, et al.: Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients. J Microbiol Immunol Infect. 2017, 50:307-315. 10.1016/j.jmii.2015.07.011

13. Fuller JD, Craven DE, Steger KA, Cox N, Heeren TC, Chernoff D: Influenza vaccine in children and adolescents: immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. AIDS. 1997, 11:1015-1021. 10.1097/00002030-199708000-00001

14. Onlamoon N, Unpol P, Boonchan M, et al.: Immune activation and viral replication after vaccine with an influenza vaccine in HIV-infected children receiving antiretroviral therapy. Dis Markers. 2015, 35:7. 10.1155/2015/276547

15. Tasker SA, Treanor JJ, Paxton WB, Wallace MR: Efficacy of influenza vaccination in HIV-infected persons: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999, 131:430-433. 10.7326/0003-4819-131-6-199909210-00006

16. Fuller JD, Craven DE, Steger KA, Cox N, Heeren TC, Chernoff D: Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis. 1999, 28:541-547. 10.1086/515170

17. Onlamoon N, Unpol P, Boonchan M, et al.: Immune activation and viral replication after vaccine with an influenza vaccine in HIV-infected children receiving antiretroviral therapy. Dis Markers. 2015, 35:7. 10.1155/2015/276547

18. Tasker SA, Treanor JJ, Paxton WB, Wallace MR: Efficacy of influenza vaccination in HIV-infected persons: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999, 131:430-433. 10.7326/0003-4819-131-6-199909210-00006

19. Skiest DJ, Machala T: Comparison of the effects of acute influenza infection and influenza vaccination on HIV viral load and CD4 cell counts. J Clin Virol. 2005, 26:307-315. 10.1016/s1386-6532(02)00047-1

20. Beck CR, McKenzie BC, Hashim AB, Harris RC; University of Nottingham Influenza and the ImmunoCompromised (UNIC) Study Group, Nguyen-Van-Tam JS: Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis. 2012, 206:1250-1259. 10.1093/infdis/jis487